	US 11,806,390 B2
	Fusion proteins comprising an anti-CD40 antibody and cancer antigens
Gerard Zurawski, Midlothian, TX (US); Jacques F. Banchereau, Montclair, NJ (US); Anne-Laure Flamar, New York, NY (US); Peter Klucar, Magnolia, AR (US); Keiko Akagawa, Tokyo (JP); Sandra Zurawski, Midlothian, TX (US); and SangKon Oh, Baltimore, MD (US)
Assigned to BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed by BAYLOR RESEARCH INSTITUTE, Dallas, TX (US)
Filed on Apr. 12, 2021, as Appl. No. 17/301,704.
Application 17/301,704 is a division of application No. 15/703,685, filed on Sep. 13, 2017, granted, now 10,980,869.
Application 14/819,909 is a division of application No. 12/717,778, filed on Mar. 4, 2010, granted, now 9,102,734, issued on Aug. 11, 2015.
Application 15/703,685 is a continuation of application No. 14/819,909, filed on Aug. 6, 2015, abandoned.
Claims priority of provisional application 61/159,055, filed on Mar. 10, 2009.
Claims priority of provisional application 61/159,059, filed on Mar. 10, 2009.
Claims priority of provisional application 61/159,062, filed on Mar. 10, 2009.
Prior Publication US 2021/0308242 A1, Oct. 7, 2021
Int. Cl. A61K 39/00 (2006.01); A61K 39/385 (2006.01); C07K 14/005 (2006.01); C07K 16/00 (2006.01); G01N 33/68 (2006.01); C07K 16/28 (2006.01); C07K 14/435 (2006.01)

CPC A61K 39/001129 (2018.08) [A61K 39/385 (2013.01); C07K 14/005 (2013.01); C07K 14/435 (2013.01); C07K 16/00 (2013.01); C07K 16/2878 (2013.01); G01N 33/6863 (2013.01); A61K 39/00 (2013.01); A61K 2039/6056 (2013.01); A61K 2039/627 (2013.01); A61K 2039/64 (2013.01); C07K 2317/41 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/74 (2013.01); C07K 2317/77 (2013.01); C07K 2317/80 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); C07K 2319/40 (2013.01); C07K 2319/91 (2013.01); C12N 2740/16222 (2013.01); C12N 2740/16322 (2013.01); C12N 2760/16122 (2013.01); C12N 2770/24222 (2013.01); C12N 2770/24234 (2013.01); Y02A 50/30 (2018.01)]

14 Claims

1. A method for inducing cytotoxic T-cell response against tumor cells in a human subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a fusion protein, wherein the fusion protein comprises an anti-CD40 antibody or antigen-binding fragment thereof linked to one or more cancer antigens expressed by the tumor cells; wherein the anti-CD40 antibody or antibody-binding fragment thereof comprises a light chain variable region comprising a CDR1L, CDR2L, and CDR3L of SEO ID NO:41, 42, and 43, respectively, and a heavy chain variable region comprising a CDR1H, CDR2H, and CDR3H of SEO ID NO:44, 45, and 46, respectively.